Stock Analysis

Estimating The Intrinsic Value Of SciBase Holding AB (publ) (STO:SCIB)

OM:SCIB
Source: Shutterstock

Key Insights

  • The projected fair value for SciBase Holding is kr0.44 based on 2 Stage Free Cash Flow to Equity
  • SciBase Holding's kr0.45 share price indicates it is trading at similar levels as its fair value estimate
  • Peers of SciBase Holding are currently trading on average at a 35% discount

Does the April share price for SciBase Holding AB (publ) (STO:SCIB) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and discounting them to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward.

Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.

Crunching The Numbers

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate:

10-year free cash flow (FCF) forecast

2025202620272028202920302031203220332034
Levered FCF (SEK, Millions) -kr43.0m-kr48.0mkr4.00mkr5.34mkr6.61mkr7.74mkr8.70mkr9.48mkr10.1mkr10.6m
Growth Rate Estimate SourceAnalyst x1Analyst x1Analyst x1Est @ 33.50%Est @ 23.84%Est @ 17.08%Est @ 12.34%Est @ 9.03%Est @ 6.71%Est @ 5.09%
Present Value (SEK, Millions) Discounted @ 5.8% -kr40.7-kr42.9kr3.4kr4.3kr5.0kr5.5kr5.9kr6.1kr6.1kr6.1

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = -kr41m

The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 1.3%. We discount the terminal cash flows to today's value at a cost of equity of 5.8%.

Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = kr11m× (1 + 1.3%) ÷ (5.8%– 1.3%) = kr241m

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= kr241m÷ ( 1 + 5.8%)10= kr138m

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is kr96m. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of kr0.4, the company appears around fair value at the time of writing. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

dcf
OM:SCIB Discounted Cash Flow April 4th 2025

Important Assumptions

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at SciBase Holding as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 5.8%, which is based on a levered beta of 1.032. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

See our latest analysis for SciBase Holding

SWOT Analysis for SciBase Holding

Strength
  • Currently debt free.
Weakness
  • Shareholders have been diluted in the past year.
Opportunity
  • Forecast to reduce losses next year.
  • Good value based on P/S ratio compared to estimated Fair P/S ratio.
Threat
  • Has less than 3 years of cash runway based on current free cash flow.

Looking Ahead:

Whilst important, the DCF calculation is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For SciBase Holding, there are three further elements you should consider:

  1. Risks: Every company has them, and we've spotted 5 warning signs for SciBase Holding (of which 2 shouldn't be ignored!) you should know about.
  2. Future Earnings: How does SCIB's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart .
  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St updates its DCF calculation for every Swedish stock every day, so if you want to find the intrinsic value of any other stock just search here.

If you're looking to trade SciBase Holding, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Sponsored Content

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OM:SCIB

SciBase Holding

A medical technology company, develops and sells point-of-care platforms that utilizes electrical impedance spectroscopy for the evaluation of skin disorders in Europe, the United States, North America, Asia, Oceania, and internationally.

Exceptional growth potential moderate.